Vikram Fielding-Singh1, Michael A Matthay2, Carolyn S Calfee2. 1. Department of Anesthesiology and Perioperative Medicine, University of California Los Angeles, Los Angeles, CA. 2. Departments of Medicine and Anesthesia, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA.
Abstract
OBJECTIVES: Despite decades of research, the acute respiratory distress syndrome remains associated with significant morbidity and mortality. This Concise Definitive Review provides a practical and evidence-based summary of treatments in addition to low tidal volume ventilation and their role in the management of severe respiratory failure in acute respiratory distress syndrome. DATA SOURCES: We searched the PubMed database for clinical trials, observational studies, and review articles describing treatment adjuncts in acute respiratory distress syndrome patients, including high positive end-expiratory pressure strategies, recruitment maneuvers, high-frequency oscillatory ventilation, neuromuscular blockade, prone positioning, inhaled pulmonary vasodilators, extracorporeal membrane oxygenation, glucocorticoids, and renal replacement therapy. STUDY SELECTION AND DATA EXTRACTION: Results were reviewed by the primary author in depth. Disputed findings and conclusions were then reviewed with the other authors until consensus was achieved. DATA SYNTHESIS: Severe respiratory failure in acute respiratory distress syndrome may present with refractory hypoxemia, severe respiratory acidosis, or elevated plateau airway pressures despite lung-protective ventilation according to acute respiratory distress syndrome Network protocol. For severe hypoxemia, first-line treatment adjuncts include high positive end-expiratory pressure strategies, recruitment maneuvers, neuromuscular blockade, and prone positioning. For refractory acidosis, we recommend initial modest liberalization of tidal volumes, followed by neuromuscular blockade and prone positioning. For elevated plateau airway pressures, we suggest first decreasing tidal volumes, followed by neuromuscular blockade, modification of positive end-expiratory pressure, and prone positioning. Therapies such as inhaled pulmonary vasodilators, glucocorticoids, and renal replacement therapy have significantly less evidence in favor of their use and should be considered second line. Extracorporeal membrane oxygenation may be life-saving in selected patients with severe acute respiratory distress syndrome but should be used only when other alternatives have been applied. CONCLUSIONS: Severe respiratory failure in acute respiratory distress syndrome often necessitates the use of treatment adjuncts. Evidence-based application of these therapies in acute respiratory distress syndrome remains a significant challenge. However, a rational stepwise approach with frequent monitoring for improvement or harm can be achieved.
OBJECTIVES: Despite decades of research, the acute respiratory distress syndrome remains associated with significant morbidity and mortality. This Concise Definitive Review provides a practical and evidence-based summary of treatments in addition to low tidal volume ventilation and their role in the management of severe respiratory failure in acute respiratory distress syndrome. DATA SOURCES: We searched the PubMed database for clinical trials, observational studies, and review articles describing treatment adjuncts in acute respiratory distress syndromepatients, including high positive end-expiratory pressure strategies, recruitment maneuvers, high-frequency oscillatory ventilation, neuromuscular blockade, prone positioning, inhaled pulmonary vasodilators, extracorporeal membrane oxygenation, glucocorticoids, and renal replacement therapy. STUDY SELECTION AND DATA EXTRACTION: Results were reviewed by the primary author in depth. Disputed findings and conclusions were then reviewed with the other authors until consensus was achieved. DATA SYNTHESIS: Severe respiratory failure in acute respiratory distress syndrome may present with refractory hypoxemia, severe respiratory acidosis, or elevated plateau airway pressures despite lung-protective ventilation according to acute respiratory distress syndrome Network protocol. For severe hypoxemia, first-line treatment adjuncts include high positive end-expiratory pressure strategies, recruitment maneuvers, neuromuscular blockade, and prone positioning. For refractory acidosis, we recommend initial modest liberalization of tidal volumes, followed by neuromuscular blockade and prone positioning. For elevated plateau airway pressures, we suggest first decreasing tidal volumes, followed by neuromuscular blockade, modification of positive end-expiratory pressure, and prone positioning. Therapies such as inhaled pulmonary vasodilators, glucocorticoids, and renal replacement therapy have significantly less evidence in favor of their use and should be considered second line. Extracorporeal membrane oxygenation may be life-saving in selected patients with severe acute respiratory distress syndrome but should be used only when other alternatives have been applied. CONCLUSIONS: Severe respiratory failure in acute respiratory distress syndrome often necessitates the use of treatment adjuncts. Evidence-based application of these therapies in acute respiratory distress syndrome remains a significant challenge. However, a rational stepwise approach with frequent monitoring for improvement or harm can be achieved.
Authors: Allan J Walkey; Lorenzo Del Sorbo; Carol L Hodgson; Neill K J Adhikari; Hannah Wunsch; Maureen O Meade; Elizabeth Uleryk; Dean Hess; Daniel S Talmor; B Taylor Thompson; Roy G Brower; Eddy Fan Journal: Ann Am Thorac Soc Date: 2017-10
Authors: Moronke A Noah; Giles J Peek; Simon J Finney; Mark J Griffiths; David A Harrison; Richard Grieve; M Zia Sadique; Jasjeet S Sekhon; Daniel F McAuley; Richard K Firmin; Christopher Harvey; Jeremy J Cordingley; Susanna Price; Alain Vuylsteke; David P Jenkins; David W Noble; Roxanna Bloomfield; Timothy S Walsh; Gavin D Perkins; David Menon; Bruce L Taylor; Kathryn M Rowan Journal: JAMA Date: 2011-10-05 Impact factor: 56.272
Authors: Andrew Davies; Daryl Jones; Michael Bailey; John Beca; Rinaldo Bellomo; Nikki Blackwell; Paul Forrest; David Gattas; Emily Granger; Robert Herkes; Andrew Jackson; Shay McGuinness; Priya Nair; Vincent Pellegrino; Ville Pettilä; Brian Plunkett; Roger Pye; Paul Torzillo; Steve Webb; Michael Wilson; Marc Ziegenfuss Journal: JAMA Date: 2009-10-12 Impact factor: 56.272
Authors: Robert M Kacmarek; Jesús Villar; Demet Sulemanji; Raquel Montiel; Carlos Ferrando; Jesús Blanco; Younsuck Koh; Juan Alfonso Soler; Domingo Martínez; Marianela Hernández; Mauro Tucci; Joao Batista Borges; Santiago Lubillo; Arnoldo Santos; Juan B Araujo; Marcelo B P Amato; Fernando Suárez-Sipmann Journal: Crit Care Med Date: 2016-01 Impact factor: 7.598
Authors: Sergi Vaquer; Candelaria de Haro; Paula Peruga; Joan Carles Oliva; Antonio Artigas Journal: Ann Intensive Care Date: 2017-05-12 Impact factor: 6.925
Authors: Esteban Ortiz-Prado; Katherine Simbaña-Rivera; Lenin Gómez-Barreno; Mario Rubio-Neira; Linda P Guaman; Nikolaos C Kyriakidis; Claire Muslin; Ana María Gómez Jaramillo; Carlos Barba-Ostria; Doménica Cevallos-Robalino; Hugo Sanches-SanMiguel; Luis Unigarro; Rasa Zalakeviciute; Naomi Gadian; Andrés López-Cortés Journal: Diagn Microbiol Infect Dis Date: 2020-05-30 Impact factor: 2.803
Authors: Michael A Matthay; Rachel L Zemans; Guy A Zimmerman; Yaseen M Arabi; Jeremy R Beitler; Alain Mercat; Margaret Herridge; Adrienne G Randolph; Carolyn S Calfee Journal: Nat Rev Dis Primers Date: 2019-03-14 Impact factor: 52.329
Authors: Hannah Viola; Jonathan Chang; Jocelyn R Grunwell; Louise Hecker; Rabindra Tirouvanziam; James B Grotberg; Shuichi Takayama Journal: APL Bioeng Date: 2019-11-22